Percutaneous Biliary Stenting Combined with Radiotherapy As a Treatment for Unresectable Hilar Cholangiocarcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Dec 2

PMID 26622885

Citations 10

Authors

Yong Tan

Jian-Yong Zhu

Bao-An Qiu

Nian-Xin Xia

Jing-Han Wang

Affiliations

Soon will be listed here.

Abstract

Hilar cholangiocarcinoma is often unresectable at the time of the initial diagnosis, and the provision of a definite palliative benefit is important in patients with unresectable hilar cholangiocarcinoma. The aim of the present study was to evaluate the safety of percutaneous biliary stenting and to analyze whether percutaneous biliary stenting combined with radiotherapy (RT) prolonged the stent patency and survival time of patients. In total, the cases of 38 patients with unresectable hilar cholangiocarcinoma that underwent percutaneous biliary stenting at the Navy General Hospital were retrospectively reviewed in the present study. Uncovered metallic stenting (UMS) combined with RT was administered to 25 patients, and UMS alone was administered to 13 patients. The records of early complications subsequent to percutaneous biliary stenting were collected, and the stent patency and survival times of patients were analyzed and compared between the two groups. The technical success rate of the procedure was 100% and the successful drainage rate was 86.8%. The overall early complication rate was 15.8% and the procedure-associated mortality rate was 2.6%. The median stent patency was 326 days in the UMS+RT group and 196 days in the UMS group (P=0.022). The UMS+RT group (median, 367 days) demonstrated a longer survival time compared with the UMS group (median, 267 days; P=0.025). Percutaneous biliary stenting offers a safe and effective method for the palliative treatment of patients with unresectable hilar cholangiocarcinoma, and percutaneous biliary stenting combined with RT may prolong stent patency and patient survival time.

Citing Articles

Particle beam therapy versus photon radiotherapy for extrahepatic biliary cancer-systemic review and meta-analysis.

Yamazaki H, Kimoto T, Teramukai S, Fujikawa K, Shibuya K, Suzuki M J Radiat Res. 2023; 64(Supplement_1):i34-i40.

PMID: 37036780 PMC: 10278884. DOI: 10.1093/jrr/rrad015.

New approaches to diagnostics and treatment of cholangiocellular cancer based on photonics methods.

Yakovlev D, Farrakhova D, Shiryaev A, Efendiev K, Loschenov M, Amirkhanova L Front Optoelectron. 2023; 13(4):352-359.

PMID: 36641569 PMC: 9743847. DOI: 10.1007/s12200-020-1093-0.

Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study.

Yang P, Chen Y, Li X, Hsiao C, Cheng B, Gao Y Front Oncol. 2021; 11:710536.

PMID: 34277454 PMC: 8278819. DOI: 10.3389/fonc.2021.710536.

Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer.

Jethwa K, Sannapaneni S, Mullikin T, Harmsen W, Petersen M, Antharam P J Gastrointest Oncol. 2021; 11(6):1408-1420.

PMID: 33457010 PMC: 7807283. DOI: 10.21037/jgo-20-245.

Novel brachytherapy drainage tube loaded with double I strands for hilar cholangiocarcinoma: A case report.

Lei Q, Jiao D, Han X World J Clin Cases. 2020; 8(19):4603-4608.

PMID: 33083424 PMC: 7559681. DOI: 10.12998/wjcc.v8.i19.4603.

References

van Delden O, Lameris J . Percutaneous drainage and stenting for palliation of malignant bile duct obstruction. Eur Radiol. 2007; 18(3):448-56. DOI: 10.1007/s00330-007-0796-6. View

Shinchi H, Takao S, Nishida H, Aikou T . Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol. 2000; 75(2):89-94. DOI: 10.1002/1096-9098(200010)75:2<89::aid-jso3>3.0.co;2-v. View

Schima W, Prokesch R, Osterreicher C, Thurnher S, Fugger R, Schofl R . Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction. Clin Radiol. 1997; 52(3):213-9. DOI: 10.1016/s0009-9260(97)80275-9. View

Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N . A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut. 2004; 53(5):729-34. PMC: 1774024. DOI: 10.1136/gut.2003.018945. View

Rea D, Munoz-Juarez M, Farnell M, Donohue J, Que F, Crownhart B . Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg. 2004; 139(5):514-23. DOI: 10.1001/archsurg.139.5.514. View

Jarnagin W, Fong Y, DeMatteo R, Gonen M, BURKE E, Bodniewicz BS J . Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001; 234(4):507-17; discussion 517-9. PMC: 1422074. DOI: 10.1097/00000658-200110000-00010. View

Singhal D, van Gulik T, Gouma D . Palliative management of hilar cholangiocarcinoma. Surg Oncol. 2005; 14(2):59-74. DOI: 10.1016/j.suronc.2005.05.004. View

Kaiser G, Fruhauf N, Lang H, Sauerwein W, Sotiropoulos G, Zopf T . Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma. Hepatogastroenterology. 2009; 55(88):1951-4. View

De Palma G, Pezzullo A, Rega M, Persico M, Patrone F, Mastantuono L . Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study. Gastrointest Endosc. 2003; 58(1):50-3. DOI: 10.1067/mge.2003.310. View

10.

Inal M, Akgul E, Aksungur E, Seydaoglu G . Percutaneous placement of biliary metallic stents in patients with malignant hilar obstruction: unilobar versus bilobar drainage. J Vasc Interv Radiol. 2003; 14(11):1409-16. DOI: 10.1097/01.rvi.0000096762.74047.a6. View

11.

Indar A, Lobo D, Gilliam A, Gregson R, Davidson I, Whittaker S . Percutaneous biliary metal wall stenting in malignant obstructive jaundice. Eur J Gastroenterol Hepatol. 2003; 15(8):915-9. DOI: 10.1097/00042737-200308000-00013. View

12.

Ohnishi H, Asada M, Shichijo Y, Iijima N, Itobayashi E, Shimura K . External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology. 1995; 42(3):265-8. View

13.

Stoker J, Lameris J, van Blankenstein M . Percutaneous metallic self-expandable endoprostheses in malignant hilar biliary obstruction. Gastrointest Endosc. 1993; 39(1):43-9. DOI: 10.1016/s0016-5107(93)70009-7. View

14.

Rerknimitr R, Angsuwatcharakon P, Ratanachu-Ek T, Khor C, Ponnudurai R, Moon J . Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2013; 28(4):593-607. DOI: 10.1111/jgh.12128. View

15.

Golfieri R, Giampalma E, Fusco F, Galuppi A, Faccioli L, Galaverni C . Unresectable hilar cholangiocarcinoma: multimodality treatment with percutaneous and intraluminal plus external radiotherapy. J Chemother. 2005; 16 Suppl 5:55-7. DOI: 10.1080/1120009x.2004.11782386. View

16.

Kuvshinoff B, Armstrong J, Fong Y, Schupak K, Getradjman G, Heffernan N . Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg. 1995; 82(11):1522-5. DOI: 10.1002/bjs.1800821122. View

17.

Pinol V, Castells A, Bordas J, Real M, Llach J, Montana X . Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology. 2002; 225(1):27-34. DOI: 10.1148/radiol.2243011517. View

18.

Paik W, Park Y, Hwang J, Lee S, Yoon C, Kang S . Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc. 2008; 69(1):55-62. DOI: 10.1016/j.gie.2008.04.005. View

19.

Rossi P, Bezzi M, Rossi M, Adam A, Chetty N, Roddie M . Metallic stents in malignant biliary obstruction: results of a multicenter European study of 240 patients. J Vasc Interv Radiol. 1994; 5(2):279-85. DOI: 10.1016/s1051-0443(94)71483-4. View

20.

Kose F, Oguzkurt L, Besen A, Sumbul T, Sezer A, Karadeniz C . Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience. Eur J Radiol. 2011; 81(8):1724-7. DOI: 10.1016/j.ejrad.2011.04.056. View